C
Chris Parker
Researcher at Institute of Cancer Research
Publications - 479
Citations - 35757
Chris Parker is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 79, co-authored 422 publications receiving 30260 citations. Previous affiliations of Chris Parker include The Royal Marsden NHS Foundation Trust & University of Toronto.
Papers
More filters
Journal ArticleDOI
Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.
Veronica A. Morgan,S F Riches,Karen Thomas,N.J. VanAs,Chris Parker,Sharon L. Giles,Nandita M. deSouza +6 more
TL;DR: This pilot study shows that DW-MRI has potential for monitoring patients with early prostate cancer who opt for active surveillance with significantly reduced apparent diffusion coefficients derived from diffusion-weighted MRI.
Journal ArticleDOI
The relevance of a hypoxic tumour microenvironment in prostate cancer.
Grant D. Stewart,Grant D. Stewart,James A. Ross,Duncan B. McLaren,Chris Parker,Fouad K. Habib,Antony C. P. Riddick +6 more
TL;DR: A review of the role of low-oxygen conditions in prostate cancer and the areas where further studies are required is presented in this paper, where the authors highlight the inconsistencies and unanswered questions about the relevance of hypoxia in cancer.
Journal ArticleDOI
PROMIS — Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer
A. El-Shater Bosaily,Chris Parker,Louise Brown,Rhian Gabe,Richard Hindley,Richard Kaplan,Mark Emberton,Hashim U. Ahmed,Hashim U. Ahmed +8 more
TL;DR: Whether MP-MRI of the prostate prior to first biopsy improves the detection accuracy of clinically-significant cancer is investigated.
Journal ArticleDOI
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
TL;DR: Therapeutic targets include the adrenal steroid synthesis pathway, androgen receptor signalling, the epidermal growth factor receptor family, insulin growth factor-1 receptor, histone deacetylase, heat shock protein 90 and the tumour vasculature, and drugs against these targets are giving an insight into the molecular pathogenesis of this disease.
Journal ArticleDOI
Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
TL;DR: Quantification of activity in bone after administrations of 100 kBq/kg of 223Ra-chloride proved the feasibility of quantitative imaging of patients who have received radionuclide therapy, and demonstrated that it is possible to quantify uptake with a sufficient degree of accuracy to obtain clinically relevant information.